Steven Cohen’s Amylyx Pharmaceuticals AMLX Stock Holding History

Steven Cohen’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$136K	Buy	+7,600	New	+$118K	﹤0.01%	3637

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Steven Cohen's AMLX Position: Q2 2026 in Review

Steven Cohen sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 106,535 shares — an estimated $1.65M sold.

Steven Cohen first reported a position in AMLX in Q2 2022 and held it in 14 quarters. The position peaked at $78.6M in Q4 2022. 205 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Steven Cohen reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 106,535 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
Steven Cohen first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 14 quarters.
Steven Cohen's Amylyx Pharmaceuticals position peaked at $78.6M in Q4 2022.
205 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.